Families facing rare muscle disease are pushing for an experimental gene therapy, but the FDA is skeptical
SRP-9001, an experimental gene therapy that aims to slow or stop the progression of Duchenne muscular dystrophy, is being considered for accelerated approval by the FDA.
1970-01-01 08:00
